RVL Pharmaceuticals plc Finite-Lived Intangible Asset, Expected Amortization, Year Five
RVL Pharmaceuticals plc had Finite-Lived Intangible Asset, Expected Amortization, Year Five of $10.68 million as of 2020-03-31, per its 10-Q filed 2020-05-12.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive · last filed 2020-05-12
- 2020-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $10.68M.
- 2019-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $10.68M.
- 2019-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year Five $14.49M.
- 2019-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year Five $35.83M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Five |
|---|---|
| 2020-03-31 | $10.68M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $10.68M 10-K · filed 2020-03-19 |
| 2019-09-30 | $14.49M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $35.83M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $49.12M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $38.91M 8-K · filed 2019-12-20 |
| 2018-09-30 | $43.92M 10-Q · filed 2018-11-08 |